Journal Staff

Electrical properties and strain gauge factor of Cr/SiOx cermet films with compositions 50/50 and 70/30 wt% were investigated in order to evaluate their use in strain gauge devices. The films were deposited by flash evaporation. The microstructures and resulting phases were characterized by electron diffraction and electron microscopy. The influence of the thickness and deposition rate on the sheet resistance, the temperature coefficient of resistance and the gauge factor were investigated. The results are consistent with a mixed conduction mechanism with metallic and a thermally activated tunneling components, between interconnected and discrete conductive phases, respectively.Se investigaron las propiedades eléctricas y el factor extensométrico de películas del cermet- Cr/SiOx en composiciones 50/50 y 70/30 % en peso, para evaluar su uso en dispositivos "strain gauge". Las películas fueron depositadas por evaporación "flash". Las estructuras y fases resultantes fueron caracterizadas por microscopía y difracción de electrones. Se estudió la influencia del espesor y la velocidad del depósito sobre la resistencia laminar, el coeficiente térmico de resistencia y el factor extensométrico. Los resultados son consistentes con un mecanismo de conducción mixto, con una componente metálica y otra por efecto túnel térmicamente activado, entre fases conductoras interconectadas y discretas, respectivamente

Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009

<p>Abstract</p> <p>Background</p> <p>Early diagnosis of HIV infection can prevent morbidity and mortality as well as reduce HIV transmission. The aim of the present study was to assess prevalence, describe trends and identify factors associated with late presentation of HIV infection in Barcelona (Spain) during the period 2001-09.</p> <p>Methods</p> <p>Demographic and epidemiological characteristics of cases reported to the Barcelona HIV surveillance system were analysed. Late presentation was defined for individuals with a CD4 count below 350 cells/ml upon HIV diagnosis or diagnosis of AIDS within 3 months of HIV diagnosis. Multivariate logistic regression were used to identify predictors of late presentation.</p> <p>Results</p> <p>Of the 2,938 newly diagnosed HIV-infected individuals, 2,507 (85,3%) had either a CD4 cell count or an AIDS diagnosis available. A total of 1,139 (55.6%) of the 2,507 studied cases over these nine years were late presenters varying from 48% among men who have sex with men to 70% among heterosexual men. The proportion of late presentation was 62.7% in 2001-2003, 51.9% in 2004-2005, 52.6% in 2006-2007 and 52.1% in 2008-2009. A decrease over time only was observed between 2001-2003 and 2004-2005 (p = 0.001) but remained constant thereafter (p = 0.9). Independent risk factors for late presentation were older age at diagnosis (p < 0.0001), use of injected drugs by men (p < 0.0001), being a heterosexual men (p < 0.0001), and being born in South America (p < 0.0001) or sub-Saharan Africa (p = 0.002).</p> <p>Conclusion</p> <p>Late presentation of HIV is still too frequent in all transmission groups in spite of a strong commitment with HIV prevention in our city. It is necessary to develop interventions that increase HIV testing and facilitate earlier entry into HIV care.</p

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding: Sanofi and Regeneron Pharmaceuticals

Electrical Response to Mechanical Deformations in Cr-SiOx Cermet Thin Films (Respuesta Eléctrica a las Deformaciones Mecánicas en Películas Delgadas del Cermet Cr-SiOx)

Electrical properties and strain gauge factor of Cr/SiOx cermet films with compositions 50/50 and 70/30 wt% were investigated in order to evaluate their use in strain gauge devices. The films were deposited by flash evaporation. The microstructures and resulting phases were characterized by electron diffraction and electron microscopy. The influence of the thickness and deposition rate on the sheet resistance, the temperature coefficient of resistance and the gauge factor were investigated. The results are consistent with a mixed conduction mechanism with metallic and a thermally activated tunneling components, between interconnected and discrete conductive phases, respectively.Se investigaron las propiedades eléctricas y el factor extensométrico de películas del cermet- Cr/SiOx en composiciones 50/50 y 70/30 % en peso, para evaluar su uso en dispositivos "strain gauge". Las películas fueron depositadas por evaporación "flash". Las estructuras y fases resultantes fueron caracterizadas por microscopía y difracción de electrones. Se estudió la influencia del espesor y la velocidad del depósito sobre la resistencia laminar, el coeficiente térmico de resistencia y el factor extensométrico. Los resultados son consistentes con un mecanismo de conducción mixto, con una componente metálica y otra por efecto túnel térmicamente activado, entre fases conductoras interconectadas y discretas, respectivamente

Solute precipitation on a screw dislocation and its effects on dislocation mobility in bcc Fe

Reactor pressure vessel steels are well-known to harden and embrittle under neutron irradiation. The primary mechanism of radiation embrittlement for these bainitic steels is the obstruction of dislocation motion, mainly due to clusters or precipitates of solute atoms such as Cu, Ni, Mn, Si and P. Microstructural examinations reveal that these clusters or precipitates are often preferentially formed at dislocation lines, which are sometimes completely surrounded by segregated solute clusters. Evidence of this is provided in this work, too, which extends a previous one dedicated to edge dislocations, by studying the effect of this segregation around screw dislocations (Burgers vector b = 1/2 [111]) on the critical stress for dislocation motion. A Monte Carlo algorithm in a variance-constrained semi-grand canonical (VC-SGC) ensemble is applied to study the decoration of atoms around dislocations, by minimizing the free energy. Next, the critical stress for dislocation unpinning from the clusters is evaluated by standard molecular dynamics to analyze the effect of Cu, Ni, Mn, and P segregation in the Fe matrix. Consistently with expectations and in agreement with previous work, our results highlight that the required stress for triggering dislocation motion drastically increases due to the presence of segregated solutes. Our finding is that solute-decorated screw dislocations may be considered as practically immobile because of the strong segregation around them.Fil: Pascuet, Maria Ines Magdalena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; ArgentinaFil: Monnet, G.. No especifíca;Fil: Bonny, G.. No especifíca;Fil: Martínez, E.. Los Alamos National Laboratory; Estados UnidosFil: Lim, J.J.H.. United Kingdom Atomic Energy Authority; Reino UnidoFil: Burke, M.G.. University of Manchester; Reino UnidoFil: Malerba, L.. No especifíca

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding: Sanofi and Regeneron Pharmaceuticals